UBS lowered the firm’s price target on Cross Country Healthcare (CCRN) to $16.50 from $18.61 and keeps a Neutral rating on the shares. Cross Country Heatlhcare’s Q1 results were as expected, and the company expects the Aya deal to close int he second half of 2025, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCRN:
- Cross Country Healthcare Reports Q1 2025 Financial Results
- Cautious Hold Rating for Cross Country Healthcare Amid Revenue Decline and Market Challenges
- Cross Country Healthcare reports Q1 adjusted EPS 6c, consensus 7c
- CCRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Hold Rating Maintained for Cross Country Healthcare Amidst Profitability Decline and Pending Aya Healthcare Merger